论文部分内容阅读
用ＬＳＡＢ免疫组织化学技术，检测了ｎｍ２３－Ｈ１基因在乳腺癌的表达情况。在１４３例乳腺癌中，７６．２％呈阳性表达。ｎｍ２３－Ｈ１基因表达与患者年龄、肿瘤大小、组织学分类、分级，雌、孕激素受体状态以及ｐ１６基因表达无明显相关（Ｐ＞０．０５）；但淋巴结转移组阳性率６４．１％（４１／６４）显著低于无转移组８３．９％（５２／６２）（Ｐ＜０．０５），ｎｍ２３－Ｈ１阳性表达组的死亡率３５．７％（１０／２８），也明显低于阴性组５５．６％（５／９），提示检测ｎｍ２３－Ｈ１蛋白可能成为乳腺癌患者的一种新的预后指标。ｎｍ２３－Ｈ１和ｐ１６基因表达无明显相关性，提示二者可能通过两种不同的机制和途径影响癌转移和预后，联合检测此二种蛋白对判断乳腺癌患者的癌转移和预后更有临床意义。
Using LSAB immunohistochemical technique, the expression of nm23-H1 gene in breast cancer was detected. In 143 cases of breast cancer, 76.2% were positive. There was no significant correlation between nm23-H1 gene expression and patient age, tumor size, histological classification, grading, estrogen and progesterone receptor status, and p16 gene expression (P>0.05). However, the positive rate of lymph node metastasis was 64.1%. (41/64) was significantly lower than the non-metastasis group (83.9%, 52/62) (P<0.05), and the mortality rate in the nm23-H1 positive expression group was 35.7% (10/28), which was also significantly lower. In the negative group, 55.6% (5/9) suggested that the detection of nm23-H1 protein may become a new prognostic indicator for breast cancer patients. There was no significant correlation between the expression of nm23-H1 and p16 genes, suggesting that the two may affect cancer metastasis and prognosis through two different mechanisms and approaches. The combined detection of these two proteins has more clinical significance in judging the metastasis and prognosis of breast cancer patients. .